Valuation: Personalis, Inc.

Market Cap 1.72B 1.54B 1.42B 1.29B 2.45B 161B 2.51B 17.04B 6.79B 86.47B 6.46B 6.32B 273B P/E 2026 *
-13.7x
P/E 2027 * -16.3x
Enterprise Value 1.72B 1.54B 1.42B 1.29B 2.45B 161B 2.51B 17.04B 6.79B 86.47B 6.46B 6.32B 273B EV / Sales 2026 *
19.4x
EV / Sales 2027 * 15.5x
Free-Float
74.4%
Yield 2026 *
-
Yield 2027 * -
1 day-0.44%
1 week+0.83%
Current month+0.38%
1 month-0.75%
3 months+9.52%
6 months+165.55%
Current year+99.50%
1 week 15.52
Extreme 15.52
16.07
1 month 15.5
Extreme 15.505
16.17
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 1
Extreme 1
18.89
5 years 0.89
Extreme 0.8906
19.14
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 58 02/03/2023
Chief Executive Officer 66 31/12/2022
President 56 13/03/2026
Director TitleAgeSince
Director/Board Member 80 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
3/11/26 Sell

Chief Executive Officer

-29,112 0.0278%
18/9/26 Sell

Chief Financial Officer

-2,931 0.0028%
18/9/26 Sell

Chairperson

-3,998 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+0.83%+84.01%+1,456.86% 1.72B
+4.41%-2.63%+14.79%+31.52% 114B
-0.09%+8.98%+9.82%+116.66% 105B
-2.62%-19.72%+50.98%+567.48% 45.24B
+0.60%+9.55%+11.61%+113.54% 33.58B
-0.26%+4.79%+42.03%+81.11% 30.12B
-0.47%+4.61%+40.22%+94.58% 28.43B
+0.44%+8.84%+49.10%+439.64% 23.1B
-0.84%+0.47%-17.79%-17.79% 20.02B
-0.65%-1.16%-7.35%+30.12% 16.86B
Average +0.08%+1.22%+27.74%+291.37% 42B
Weighted average by Cap. +0.88%+1.01%+20.62%+151.35%

Financials

2026 *2027 *
Net sales 88.65M 79.5M 73.27M 66.54M 126M 8.31B 129M 877M 350M 4.45B 333M 326M 14.08B 111M 99.54M 91.74M 83.32M 158M 10.41B 162M 1.1B 438M 5.58B 417M 408M 17.63B
Net income -123M -110M -102M -92.32M -175M -11.53B -180M -1.22B -485M -6.18B -462M -452M -19.53B -104M -93.61M -86.27M -78.35M -148M -9.79B -152M -1.03B -412M -5.24B -392M -383M -16.58B
Net Debt - -
Projected Income Statement - Annual - Personalis, Inc.
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
10/11/26 USD 15.88 -0.44% 1,755,224
09/11/26 USD 15.95 +1.01% 2,324,443
06/11/26 USD 15.79 +1.54% 3,000,201
05/11/26 USD 15.55 -1.52% 3,788,458
04/11/26 USD 15.79 +0.25% 2,217,753
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Personalis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
15.88USD
Average target price
15.17USD
Spread / Average Target
-4.49%
  1. Stock Market
  2. Stocks
  3. PSNL Stock